Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of “Moderate Buy” by Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned an average rating of “Moderate Buy” from the nineteen analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $38.5882.

Several research firms have recently issued reports on DYN. Chardan Capital restated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Tuesday, December 9th. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. dropped their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, November 14th. Lifesci Capital upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Cowen reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th.

Institutional Trading of Dyne Therapeutics

A number of large investors have recently made changes to their positions in DYN. CIBC Bancorp USA Inc. bought a new position in shares of Dyne Therapeutics in the third quarter worth about $147,000. Jacobs Levy Equity Management Inc. purchased a new stake in Dyne Therapeutics in the 3rd quarter valued at about $9,230,000. Armistice Capital LLC grew its stake in Dyne Therapeutics by 19.7% in the 3rd quarter. Armistice Capital LLC now owns 3,064,000 shares of the company’s stock worth $38,760,000 after acquiring an additional 504,000 shares in the last quarter. TCG Crossover Management LLC grew its stake in Dyne Therapeutics by 22.5% in the 3rd quarter. TCG Crossover Management LLC now owns 4,615,144 shares of the company’s stock worth $58,382,000 after acquiring an additional 848,484 shares in the last quarter. Finally, Dark Forest Capital Management LP increased its position in shares of Dyne Therapeutics by 223.7% during the third quarter. Dark Forest Capital Management LP now owns 68,888 shares of the company’s stock worth $871,000 after acquiring an additional 47,604 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $19.27 on Monday. The business’s 50 day moving average price is $19.17 and its 200-day moving average price is $14.30. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $26.69. The company has a market cap of $2.75 billion, a P/E ratio of -5.27 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. Sell-side analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.